
Innovent Biologics, Inc. has initiated Phase 3 clinical trial GLORY-2, dosing the first participant with the 9 mg mazdutide, a dual agonist for glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR). The trial targets Chinese adults with obesity, enrolling 450 subjects for randomized treatment with mazdutide 9 mg or placebo. Primary endpoints include percentage change in body weight and proportion of subjects with 5% or more body weight loss at week 60. A Phase 2 study demonstrated mazdutide's efficacy and metabolic benefits with a well-tolerated safety profile.
Like
Save
Share